News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dicerna Pharmaceuticals Announces Patent Issuance for DsiRNAs Directed at the KRAS Gene, a Key Cancer Regulator


3/19/2013 10:09:55 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, today announced that the United States Patent and Trademark Office (USPTO) has issued patent claims specific to double-stranded RNAs directed against the important oncology gene target KRAS. U.S. patent 8,372,816, titled “Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA” was recently issued to Dicerna. This issuance continues the expansion of Dicerna’s patent portfolio around RNAi-related technology, including the DsiRNA class defining claims of U.S. patent 8,084,599, titled “Methods and compositions for the specific inhibition of gene expression by double-stranded RNA.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES